ELAPOR1 抑制结直肠癌的肿瘤进展并提示预后良好。

Department of General Surgery, Jinshan Hospital, Fudan University, Shanghai, China.

Department of Pathology, Jinshan Hospital, Fudan University, Shanghai, China.

Cancer Biomark. 2023;37(4):279-288. doi: 10.3233/CBM-220285.

BACKGROUND

The role of ELAPOR1 has been evaluated in several cancers but has not been elucidated in colorectal cancer (CRC).

OBJECTIVE

To investigate the role of ELAPOR1 in CRC.

METHODS

In the present study, the correlation between ELAPOR1 and survival of CRC patients in TCGA-COAD-READ datasets was predicted, and the difference in ELAPOR1 expression between tumor and normal tissues was analyzed. ELAPOR1 expression in CRC tissues was measured by immunohistochemistry. Then, ELAPOR1 and ELAPOR1-shRNA plasmids were constructed and transfected into SW620 and RKO cells. The effects were assessed by CCK-8, colony formation, transwell, and wound healing assays. Transcriptome sequencing and bioinformatics analysis were performed on the genes before and after ELAPOR1 overexpression in SW620 cells; the differentially expressed genes were substantiated by real-time quantitative reverse transcription PCR.

RESULTS

High level of ELAPOR1 is associated with favorable disease-free survival and overall survival. Compared to normal mucosa, ELAPOR1 is lower in CRC. Moreover, ELAPOR1 overexpression significantly inhibits cell proliferation and invasion in vitro in SW260 and RKO cells. Conversely, ELAPOR1-shRNA promotes CRC cell proliferation and invasion. Among the 355 differentially expressed mRNAs identified, 234 were upregulated and 121 were downregulated. Bioinformatics indicated that these genes are involved in receptor binding, plasma membrane, negative regulation of cell proliferation, as well as common cancer signaling pathways.

CONCLUSIONS

ELAPOR1 plays an inhibitory role in CRC and may be used as a prognostic indicator and a potential target for treatment.

背景

ELAPOR1 的作用在几种癌症中得到了评估，但在结直肠癌 (CRC) 中尚未阐明。

目的

研究 ELAPOR1 在 CRC 中的作用。

方法

本研究预测了 TCGA-COAD-READ 数据集 CRC 患者中 ELAPOR1 与生存的相关性，并分析了肿瘤组织和正常组织中 ELAPOR1 表达的差异。采用免疫组织化学法检测 CRC 组织中 ELAPOR1 的表达。然后构建 ELAPOR1 和 ELAPOR1-shRNA 质粒，并转染 SW620 和 RKO 细胞。通过 CCK-8、集落形成、Transwell 和划痕愈合实验评估效果。对 SW620 细胞中 ELAPOR1 过表达前后的基因进行转录组测序和生物信息学分析；通过实时定量逆转录 PCR 对差异表达基因进行验证。

结果

高水平的 ELAPOR1 与良好的无病生存率和总生存率相关。与正常黏膜相比，CRC 中 ELAPOR1 水平较低。此外，ELAPOR1 过表达可显著抑制 SW260 和 RKO 细胞体外的细胞增殖和侵袭。相反，ELAPOR1-shRNA 促进 CRC 细胞的增殖和侵袭。在鉴定的 355 个差异表达的 mRNA 中，有 234 个上调，121 个下调。生物信息学分析表明，这些基因参与受体结合、质膜、细胞增殖的负调控以及常见的癌症信号通路。